



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b>  <b>A61K 38/13</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/27946</b>  <b>(43) International Publication Date:</b> 10 June 1999 (10.06.99)																								
<b>(21) International Application Number:</b> PCT/KR98/00387 <b>(22) International Filing Date:</b> 1 December 1998 (01.12.98)  <b>(30) Priority Data:</b> 1997/65420                      2 December 1997 (02.12.97)      KR  <b>(71) Applicant (for all designated States except US):</b> CHONG KUN DANG CORP. [KR/KR]; 410, Shindorim-dong, Guro-gu, Seoul 152-070 (KR).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HONG, Chung Il [US/US]; 100 Hunt Club Circle, East Amherst, NY 14051-1870 (US). KIM, Jung, Woo [KR/KR]; 925-7, Hwagog 1-dong, Kangseo-gu, Seoul 157-011 (KR). CHOI, Nam, Hee [KR/KR]; 302-507, Daechung Apt., Gepo-dong, Kangnam-gu, Seoul 135-240 (KR). SHIN, Hee, Jong [KR/KR]; 1404-101, YonHwa Maeul, Joong 2-dong, Wonmi-gu, Buchun, Kyeonggi-do 420-022 (KR). YANG, Su, Geun [KR/KR]; 541-19, Bisan-dong, Dongan-gu, Anyang, Kyeonggi-do 431-050 (KR). KIM, Jae, Hyun [KR/KR]; 27-609, Changmi Apt., Shinchun-dong, Songpa-gu, Seoul 138-240 (KR). LIM, Jong, Lae [KR/KR]; 607-803, Chukong Apt., HaAhn-dong, Kwangmyung, Kyeonggi-do 423-060 (KR). KIM, Chong, Kook [KR/KR];		105-301, Woobang Villa, 75, Kumi-dong, Bhundang-gu, Sungnam, Kyeonggi-do 463-500 (KR).  <b>(74) Agent:</b> SUH, Jong, Wan; New-Seoul Building, 7th floor, 828-8, Yeoksam-dong, Kangnam-ku, Seoul 135-080 (KR).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>																								
<b>(54) Title:</b> PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN SOLID-STATE MICROEMULSION  <div data-bbox="462 1102 1047 1585" data-label="Figure"> <table border="1"> <caption>Estimated data points from the graph</caption> <thead> <tr> <th>Time (h)</th> <th>Blood concentration of CsA (ng/ml) - Solid Circles</th> <th>Blood concentration of CsA (ng/ml) - Open Circles</th> </tr> </thead> <tbody> <tr><td>0</td><td>0</td><td>0</td></tr> <tr><td>1</td><td>~1000</td><td>~800</td></tr> <tr><td>2</td><td>~1200</td><td>~1000</td></tr> <tr><td>4</td><td>~1100</td><td>~800</td></tr> <tr><td>8</td><td>~700</td><td>~400</td></tr> <tr><td>12</td><td>~400</td><td>~200</td></tr> <tr><td>24</td><td>~100</td><td>~50</td></tr> </tbody> </table> </div> <b>(57) Abstract</b> <p>The present invention is related to a pharmaceutical composition comprising cyclosporin as an active component. More specifically, the present invention is related to a pharmaceutical composition comprising cyclosporin solid-state microemulsion prepared by dispersing of cyclosporin microemulsion in enteric carrier. Cyclosporin solid-state microemulsion prepared according to the said description is characterized in that it does not dissolve in such external phases as artificial gastric fluid. But it can dissolve in artificial intestinal fluid, thereby getting the microemulsion form having small particle size and releasing cyclosporin rapidly. The pharmaceutical composition according to the present invention can maintain the blood concentration of cyclosporin within therapeutic range for about 1 day through only one dosing per day. Therefore, it is possible to avoid the adverse effects induced by the additional increasing of the peak level of blood cyclosporin concentration in the conventional cyclosporin preparation, and furthermore, a convenience for administration can be obtained.</p>			Time (h)	Blood concentration of CsA (ng/ml) - Solid Circles	Blood concentration of CsA (ng/ml) - Open Circles	0	0	0	1	~1000	~800	2	~1200	~1000	4	~1100	~800	8	~700	~400	12	~400	~200	24	~100	~50
Time (h)	Blood concentration of CsA (ng/ml) - Solid Circles	Blood concentration of CsA (ng/ml) - Open Circles																								
0	0	0																								
1	~1000	~800																								
2	~1200	~1000																								
4	~1100	~800																								
8	~700	~400																								
12	~400	~200																								
24	~100	~50																								

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN SOLID-STATE MICROEMULSION

### TECHNICAL FIELD

5       The present invention is related to a pharmaceutical composition comprising cyclosporin as an active component. More specifically, the present invention is related to a pharmaceutical composition comprising cyclosporin solid-state microemulsion prepared by dispersing of cyclosporin microemulsion in enteric carrier.

10

### BACKGROUND ART

Cyclosporin is a high molecular peptide compound consisting of 11 amino acids which achieves its potent immunosuppressive activity by inhibiting the growth and differentiation of T cells. There are many  
15 cyclosporins such as cyclosporin A, B, C, D, G, etc. depending on the structure of constituent amino acids, but cyclosporin A is preferably used in the clinical field since its pharmacological activity and clinical indication and effectiveness are well established in the art. Cyclosporin is used clinically to prevent allograft rejection after transplantation of tissue  
20 or organ such as kidney, liver, heart, bone marrow, pancreas, skin, cornea, etc. And it has been applied to treat autoimmune diseases, especially inflammation disease such as rheumatoid arthritis.

Cyclosporin has a unique structure, which is a cyclic oligopeptide consisting of 11 amino acids. The seven amino acids of cyclosporin are N-  
25 methylated. The four remaining protonated nitrogen atoms can form intermolecular hydrogen bonds with carbonyl groups, which contribute substantially to the rigidity of the cyclosporin skeleton. Therefore, it has a

remarkably hydrophobic property, and is relatively insoluble in water (for cyclosporin A, 0.04 mg/ml at 25°C). Due to such a low water-solubility of cyclosporin, the bioavailability of cyclosporin A is known to be 30% or less. It was reported that the absorption of such an insoluble compound is  
5 greatly influenced by bile juice secretions, the amount of fat in food, etc. In the case of cyclosporin A, it has been reported that differences in absorption between individuals are as great as about 5~50 %.

10~27% of cyclosporin A absorbed were eliminated by first-pass effect in liver. the half life for distribution of cyclosporin A is 0.7~1.7 h, and the half life for elimination of cyclosporin A is 6.2~23.9 h. The said  
10 pharmacological parameters show a large individual difference according to bile juice secretion, the condition of patient transplanted and the kind of transplantation organ.

Even though cyclosporin has almost no bone marrow toxicity  
15 unlike other immunosuppressants, it has a very narrow therapeutic range. Nephrotoxicity is the major adverse effect of cyclosporin. Cyclosporin shows adverse effects such as decreasing of glomerular filtration rate, increasing of reabsorption of proximal tubules, etc., dose-dependently. It has been reported that the appearance of an irreversible deterioration of  
20 nephron and the inducement of serious nephrotoxicity is a chronic toxicity of cyclosporin multiple dosing.

Therefore, such problems as low bioavailability due to poor aqueous solubility of cyclosporin, individual difference of cyclosporin absorption, narrow therapeutic range, adverse effects showed dose-  
25 dependently, etc., must be addressed. And recently, it has come to light that the prevention of adverse effects through a constant maintenance of blood concentration of cyclosporin within the therapeutic range is a

difficult but important objective.

In various methods for improvement of nephrotoxicity of cyclosporin, using of prostaglandin derivatives that are antagonists for calcium was tried but it did not show good effect. The risk of the high fluctuation index for rejection and for nephrotoxicity might be mitigated by frequent administration of small doses, thereby maintaining blood concentration of cyclosporin within the therapeutic range. But the administration more than thrice daily is not preferable because cyclosporin usually should be administered for a long period and, in this case, because it is difficult that patient compliance would be high. Therefore, the development of a once a day dosage form of cyclosporin is preferable and expected.

Dosage form development studies of cyclosporin having the said characteristics had been mainly concentrated on the means that are used to solubilize cyclosporin.

The soft gelatin capsule that is commercialized by Sandoz Pharmaceuticals since 1990 can form a crude emulsion in the gastric-intestinal (GI) tract after oral administration. Even though it could produce the great convenience for administration method, it still has the problem that blood concentration of cyclosporin must be monitored frequently. It was because cyclosporin absorption from the said pharmaceutical preparation showed not only large individual difference but also high variability in the same patient depending on food, bile secretion, GI tract function, etc.

Recently, to solve the said problem, a new cyclosporin-preparation using microemulsion system has been developed by Novartis (Sandimmun Neoral). This pharmaceutical preparation shows that cyclosporin

bioavailability is almost not affected by food, bile secretion, etc. as well as increasing of its bioavailability. Therefore, frequent monitoring of the trough level of patient is not needed, and hence is a remarkable improvement of pharmaceutical art.

5 U. S. Patent No. 4,146,499 disclosed the method using w/o microemulsion using ethanol as a hydrophilic cosurfactant. And U. S. Patent No. 5,342,625 disclosed the method using non-ethanol component as a hydrophilic cosurfactant to improve the disadvantage of using ethanol.

However, the said cyclosporin microemulsion compositions still  
10 have a problem of adverse effects induced by the peak level of blood concentration of cyclosporin. Therefore, a standard dose is administered to all patients initially, and then the blood concentration of cyclosporin must be monitored continuously on each patient. Inconveniently, dose of cyclosporin must be controlled referring to monitoring result, so that  
15 allograft rejection and nephrotoxicity would be minimized.

The objective of present invention is the produce of a controlled release preparation that can release cyclosporin for a long time in GI tract after oral administration, while solving the problems of cyclosporin preparations of prior arts.

20

## DISCLOSURE OF INVENTION

The present invention relates to a pharmaceutical composition comprising cyclosporin solid-state microemulsion. Cyclosporin solid-state microemulsion is a solidified product comprising cyclosporin  
25 microemulsion and carrier component. More specifically, it can be prepared by dispersing of cyclosporin microemulsion in enteric carrier.

The first essential component of the pharmaceutical composition comprising cyclosporin solid-state microemulsion according to the present invention is cyclosporin microemulsion. A microemulsion comprises two or more immiscible liquid materials together with surfactant like emulsion, but is a thermodynamically stable and optically transparent composition unlike emulsion. And the microemulsion has very low surface tension and small particle size of less than 100 nm, which together result in high absorption and permeation properties of drug delivered by microemulsion. In pharmaceutical composition according to the present invention, any one(s) of conventional cyclosporin microemulsions can be used, but preferable ones are those that do not contain such volatile materials as ethanol, etc. It is because solidifying step is needed in the preparation of cyclosporin solid-state microemulsion.

The terms "cyclosporin microemulsion" and "cyclosporin solid-state microemulsion" used in the present invention are brief expressions for "microemulsion preconcentrate containing cyclosporin" and "solidified product of microemulsion preconcentrate containing cyclosporin", respectively. The terms mean that they can form microemulsion spontaneously after being dissolved in such external phases as water, etc.

The second essential component of the pharmaceutical composition according to the present invention is enteric carrier, which is to be used in the preparation of cyclosporin solid-state microemulsion.

The action of carrier in the pharmaceutical composition according to the present invention is that of serving within the cyclosporin solid-state microemulsion prepared with the said carrier to prevent of the release of cyclosporin in acidic condition, while allowing a rapid release in neural or alkali condition. That is, cyclosporin solid-state microemulsion must not

release cyclosporin in the stomach, rather releasing it rapidly in the upper part of the small intestine. Furthermore, The particle size (inner phase diameter) of microemulsion formed in the small intestine must be sufficiently small and, therefore, capable of being maintained at 100 nm or  
5 below.

The enteric carriers that can be used in the preparation of cyclosporin solid-state microemulsion are Eudragit, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), sodium alginate, etc. Examples of Eudragit are Eudragit L100, Eudragit  
10 S100, Eudragit RS100, etc. and Eudragit L100 can be used preferably. Examples of HPMCP are HPMCP H-50, HPMCP H-55, etc. and HPMCP H-55, which is very soluble in such organic solvent as acetone, can be used preferably. CAP is also useful as an enteric carrier. In the case of using sodium alginate, such additional component as disintegrant is needed  
15 additionally because cyclosporin solid-state microemulsion prepared is disintegrated slowly.

In the pharmaceutical composition according to the present invention, one member or mixture of the said carrier materials can be used as a carrier in cyclosporin solid-state microemulsion. And the carrier  
20 component may further contain any pharmaceutically acceptable additives as needed. Examples of the said additives include antioxidant, disintegrant, dissolution control agent, flavor, plasticizer, preservatives, coloring agents, etc.

In the pharmaceutical composition according to the present  
25 invention, cyclosporin solid-state microemulsion can be prepared preferably with cyclosporin microemulsion and carrier in the range of 1: 0.1~3, or more preferably 1: 0.2~2 by weight.



The cyclosporin solid-state microemulsion, which is comprised in the pharmaceutical composition of the present invention, can be prepared by any one of methods that can produce the solidified product of the state that cyclosporin microemulsion is dispersed in carrier. A specific example  
5 is when cyclosporin microemulsion is added to the solution of carrier, and mixed to be homogeneous. The solvent is then removed by such a method as evaporation under reduced pressure, spray drying, etc., resulting in solidification.

The pharmaceutical composition of the present invention may  
10 comprise cyclosporin microemulsion together as well as cyclosporin solid-state microemulsion. To maximize the convenience of clinical usage, the pharmaceutical composition containing cyclosporin microemulsion and cyclosporin solid-state microemulsion in the proper mixing ratio can be selected, prepared in the proper dosage form (for example, the  
15 pharmaceutical composition is filled in soft capsule or hard capsule), and then used. In the pharmaceutical composition of the present invention, the mixing ratio of cyclosporin microemulsion and cyclosporin solid-state microemulsion is preferably in the range of 1 : 0.1~5, or more preferably 1 : 0.5~2 by weight.

20 Moreover, cyclosporin microemulsion and cyclosporin solid-state microemulsion, comprised in the pharmaceutical composition of the present invention, can be prepared also in the pharmaceutical preparations independently from one another, and then administered. For example, they can be filled in soft capsule and hard capsule, respectively, and then  
25 administered together.

The pharmaceutical composition according to the present invention

is characterized in that it does not dissolve in such external phases as water and artificial gastric fluid but dissolves in artificial intestinal fluid, thereby getting the microemulsion form. And by varying the mixing ratio of the components, the inner phase diameter of the microemulsion formed can be  
5 controlled easily to be 100 nm or below.

The pharmaceutical composition of the present invention, which is prepared according to the said descriptions, can maintain the blood concentration of cyclosporin within therapeutic range for about 1 day through only one dosing per day. Furthermore, it can avoid such adverse  
10 effects of cyclosporin as nephrotoxicity, etc. that originate from the high blood cyclosporin concentration.

### BRIEF DESCRIPTION OF THE DRAWINGS

For a thorough understanding of the nature and objects of the  
15 invention, reference should be noted according to the following detailed description taken in connection with the accompanying drawings in which:

Figure 1 shows release of cyclosporin solid-state microemulsions prepared using various different ratios Eudragit L100 to cyclosporin microemulsion. Key: ○, Experimental example 1-A; △, Experimental  
20 example 1-B; and □, Experimental example 1-C.

Figure 2 shows the mean blood cyclosporin concentrations following the single oral administration of cyclosporin microemulsion (○) (equivalent to 100 mg of cyclosporin A) to dogs and following the single oral combination administration (●) of cyclosporin microemulsion  
25 (equivalent to 100 mg of cyclosporin A) and cyclosporin solid-state microemulsion cyclosporin (equivalent to 100 mg of cyclosporin A) to dogs.

## MODES FOR CARRYING OUT THE INVENTION

The present invention is described in more detail by the Examples and Experiment as shown below but is not restricted to them.

### Example 1.

50 g of Eudragit L100, as an enteric carrier, was dissolved completely in acetone. 50g of cyclosporin microemulsion prepared with the composition of Table 1 was added into the carrier solution and mixed homogeneously. The solution was then evaporated slowly at 30~60°C under reduced pressure to remove the solvent completely. Cyclosporin solid-state microemulsion film produced was powdered, and formulated into pharmaceutical preparations, that is, capsule, powder, granule and tablet according to conventional methods.

Table 1.

Components	Amount per one dose (mg)
Cyclosporin A	100
Medium chain triglyceride	185
Cremophor RH 40	365
Mono- and di-glyceride	72.5
Poloxamer 124	72.5
Propylene carbonate	205

### Example 2.

The pharmaceutical preparations comprising cyclosporin solid-

state microemulsion were prepared in the same manner as Example 1 except using HPMCP instead of Eudragit L100.

### **Example 3.**

5        The pharmaceutical preparations comprising cyclosporin solid-state microemulsion were prepared in the same manner as Example 1 except using CAP instead of Eudragit L100.

### **Example 4.**

10        10 g of sodium alginate, as an enteric carrier, was dissolved completely in water thereby to be 2% aqueous solution. 50g of cyclosporin microemulsion prepared with the composition of Table 1 was added into the carrier solution and mixed homogeneously. The solution was then dropwised into 0.2M calcium chloride solution to produce alginate beads.  
15        The alginate beads comprising cyclosporin microemulsion were separated and dried. Cyclosporin solid-state microemulsion produced was powdered, and formulated into pharmaceutical preparations, that is, capsule, powder, granule and tablet according to conventional methods.

### **Example 5.**

20        The pharmaceutical preparations comprising cyclosporin solid-state microemulsion were prepared in the same manner as Example 4 except additionally using polyethylene oxide of 5 g as a dissolution control agent.

25

### **Example 6.**

50 g of cyclosporin microemulsion prepared with the composition

of Table 1 was mixed with 100 g of the powder of cyclosporin solid-state microemulsion prepared in Example 1. And the resulting composition was poured to a machine for preparing soft capsules and then encapsulated according to conventional methods for producing soft capsules. Each capsules contained 100 mg of cyclosporin A.

#### Example 7.

With 100 g of the powder of cyclosporin solid-state microemulsion prepared in Example 1, 50 g of cyclosporin microemulsion prepared with proper composition was mixed. And the resulting composition was filled in hard gelatin capsules. The conjugated portion of the hard capsules was sealed with gelatin banding to produce hard capsules containing 100 mg of cyclosporin A per capsule.

#### Example 8~14.

The pharmaceutical preparations comprising cyclosporin solid-state microemulsion were prepared in the same manner as Example 1~7 except using cyclosporin microemulsion of Table 2 instead of one of Table 1.

Table 2.

Components	Amount per one dose (mg)
Cyclosporin A	100
1,2-Propylene glycol	75
Ethanol	150
Refined trans-esterification products of corn oil and glycerol (MAISINE)	345
Cremophor RH 40	405

**Example 15~21.**

The pharmaceutical preparations comprising cyclosporin solid-state microemulsion were prepared in the same manner as Example 1~7 except  
5 using cyclosporin microemulsion of Table 3 instead of one of Table 1.

Table 3.

Components	Amount per one dose (mg)
Cyclosporin A	100
Triacetin	210
Cremophor RH 40	430
Tween 20	70
Cremophor EL	70
Poloxamer 124	70
Linoleic acid	115
Labrafac CC	285

The cyclosporin solid-state microemulsion in the pharmaceutical  
10 composition of the present invention was designed that it does not release cyclosporin in acidic condition, but can release rapidly in neutral or alkali condition. Therefore, the release test and the absorption test in dogs were performed to prove the characteristics designed.

**15 Experimental example 1. Release test**

Test sample preparation 1-A was prepared as follows:

50 g of Eudragit L100, as an enteric carrier, was dissolved completely in acetone. 50g of cyclosporin microemulsion prepared with the composition of Table 1 was added into the carrier solution and mixed homogeneously. The solution was then evaporated slowly at 30~60°C under reduced pressure to remove the solvent completely. Cyclosporin solid-state microemulsion film produced was powdered, and filled in hard capsules to contain 50 mg of cyclosporin A per capsule. The conjugated portion of the hard capsules was sealed with gelatin banding.

Test samples 1-B and 1-C were prepared in the same manner with test sample preparation 1-A except amount of Eudragit L100 used, demonstrated in Table 4.

Table 4.

Components	Amount used for preparation of cyclosporin solid-state microemulsion (g/batch)		
	Experimental example 1-A	Experimental example 1-B	Experimental example 1-C
Cyclosporin microemulsion	50	50	50
Eudragit L100	50	75	100

The release test was performed according to USP XXIII dissolution apparatus II procedure. The paddle was set at the level of 2.5-cm distance from the bottom of the vessel. Samples equivalent to 100 mg of cyclosporin A encapsulated in hard gelatin capsule was loaded in 500 ml of simulated gastric fluid (pH 1.2) (1st fluid) at  $37.0 \pm 0.5^{\circ}\text{C}$  with stirring

speed of 100 rpm. Each sample (4 ml) was withdrawn at 0, 30, 60, 90 and 120 min with compensation of equal volume of dissolution medium.

After completion of release test in the simulated gastric fluid for 120 min, 400 ml of 0.235 M sodium phosphate monobasic solution was immediately added into the vessel to adjust pH 6.8 (2nd fluid). Aliquots (4 ml) of the sample were taken at 10, 20, 30, 40, 50 and 60 min with compensation of equal volume of the mixture (5:4) of simulated gastric fluid and 0.235 M sodium phosphate monobasic solution.

The cyclosporin A concentrations of the samples were determined by HPLC at the following condition:

HPLC system --- Hewlet Packard (USA)

Column --- Capsellpak C<sub>18</sub>

Mobile phase --- Acetonitrile : Methanol : Phosphoric acid buffer [65 : 5 : 30]

Flow rate --- 2.0 ml/min

Detector wavelength --- 215 nm.

The result of the release test was shown in Fig. 1. The cyclosporin solid-state microemulsion in the pharmaceutical composition of the present invention was stable in simulated gastric fluid and then released cyclosporin in simulated intestinal fluid rapidly and completely.

### Experimental example 2. Absorption test in dogs

Ten male dogs, weighing  $15 \pm 2$  kg, were used, and each groups consisted of five dogs. No food, only water was supplied to dogs for 18 h prior to drug administration. Test sample preparation 1-A (cyclosporin solid-state microemulsion) and soft capsule of Table 1 (cyclosporin



microemulsion) were administered to dogs in a combination manner with dose of cyclosporin A 100 mg per dog per pharmaceutical preparation, and then 30~40 ml of water was administered immediately. After 4 h from drug administration, food was provided. Venous blood samples of 3 ml  
5 was withdrawn in the cephalic vein before drug administration for baseline cyclosporin A levels, and at schedule time intervals, that is 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8 and 12 h, after dosing. Blood samples were frozen under -18°C until assay. Blood concentrations of cyclosporin A were analyzed by RIA (radioimmunoassay) method.

10 The dog-whole blood cyclosporin A concentration vs. time curves of each preparation are presented in Fig. 2. It shows that administration of the pharmaceutical composition comprising cyclosporin microemulsion and cyclosporin solid-state microemulsion according to the present invention could maintain trough level above the lower limit of therapeutic range for  
15 about 24 h without additional increase of peak blood level.

In conclusion, the pharmaceutical composition of the present invention, which comprises a solidified product of cyclosporin microemulsion of prior arts, can maintain the blood concentration of  
20 cyclosporin A within therapeutic range for about 1 day through only one dosing per day. Therefore, it is possible to avoid the adverse effects, such as nephrotoxicity, etc., induced by the additional increasing of the peak level of blood cyclosporin concentration in the conventional cyclosporin preparation, and furthermore, a convenience for administration can be  
25 obtained.

## CLAIMS


1. A pharmaceutical composition comprising cyclosporin solid-state microemulsion.
- 5 2. A pharmaceutical composition according to claim 1, wherein cyclosporin is cyclosporin A.
3. A pharmaceutical composition according to claim 1, wherein cyclosporin solid-state microemulsion is a solidified product comprising cyclosporin microemulsion and carrier.
- 10 4. A pharmaceutical composition according to claim 3, wherein carrier is at least one of enteric polymer materials.
5. A pharmaceutical composition according to claim 4, wherein enteric polymer materials are Eudragit, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate and sodium alginate.
- 15 6. A pharmaceutical composition according to claim 5, wherein Eudragit is Eudragit L100 and hydroxypropyl methylcellulose phthalate is HPMCP HP-55.
7. A pharmaceutical composition according to any one of claims 3 to 6, wherein cyclosporin microemulsion and carrier that are composed  
20 cyclosporin solid-state microemulsion are present in the mixing ratio of 1 : 0.1~3 by weight.
8. A pharmaceutical composition comprising cyclosporin microemulsion and cyclosporin solid-state microemulsion.
9. A pharmaceutical composition according to claim 8, wherein  
25 cyclosporin microemulsion and cyclosporin solid-state microemulsion are present in the mixing ratio of 1 : 0.1~5 by weight.
10. A pharmaceutical composition according to claim 9, wherein

cyclosporin microemulsion and cyclosporin solid-state microemulsion are present in the mixing ratio of 1 : 0.5~2 by weight.

11. A pharmaceutical formulation comprising the composition according to claims 8, wherein the dosage form is a soft capsule or a hard capsule  
5 filled with a mixture of cyclosporin solid-state microemulsion and cyclosporin microemulsion.


1/2

FIG. 1



2/2

FIG. 2



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR 98/00387

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>6</sup>: A 61 K 38/13

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>6</sup>: A 61 K 38/13

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, CAS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97/22 358 A1 (SHERMAN) 26 June 1997 (26.06.97), abstract; page 1, lines 11-14; page 3, lines 16,17.	1,2,8,11
A	GB 2 257 359 A (SANDOZ LTD.) 13 January 1993 (13.01.93), page 1; fig. 2.	1,8,11
A	Database WPI on Questel, week 44; London, Derwent Publications Ltd., AN 92-361 896, JP 4-264 021 A (TEIKOKU SEIYAKU KK) 18 September 1992 (18.09.92), abstract.	1,5,6
A	Chemical Abstracts, vol. 94, no. 18, 04 May 1981 (Columbus, Ohio, USA), page 369, right column, abstract-no. 145 283v, PIROS "Comparative examination of hydroxypropylmethylcellulose phthalate (HPMCP) and of Eudragit (polyacrylate) preparations, as well as of their combined application". Gyogyszereszet 1980, 24 (12), 460-6(Hung), abstract.	4,5,6

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents: „A“ document defining the general state of the art which is not considered to be of particular relevance „E“ earlier application or patent but published on or after the international filing date „L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) „O“ document referring to an oral disclosure, use, exhibition or other means „P“ document published prior to the international filing date but later than the priority date claimed	„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention „X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone „Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art „&“ document member of the same patent family
--	--

Date of the actual completion of the international search

17 February 1999 (17.02.99)

Date of mailing of the international search report

26 February 1999 (26.02.99)

Name and mailing address of the ISA/AT

Austrian Patent Office  
Kohlmarkt 8-10; A-1014 Vienna  
Facsimile No. 1/53424/535

Authorized officer

Mosser

Telephone No. 1/53424/435

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 98/00387

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WD A1	9722358	26-06-97	AU A1 76885/96	14-07-97
			CA AA 2240640	26-06-97
			NZ A 280689	22-08-97
GB A	2257359		AT A 1298/92	15-07-97
			AT B 403436	25-02-98
			AU A1 18527/92	11-03-98
			AU B2 659460	18-05-98
			AU A1 28337/95	22-11-98
			CA AA 2072509	28-12-98
			CA C 2072509	30-07-96
			CH A 684163	29-07-96
			CH A 685764	29-09-96
			CZ A3 9301977	13-01-98
			CZ B6 2281790	15-01-97
			DE A1 4219526	18-03-98
			EP A1 520949	20-12-98
			EP A2 520949	20-12-98
			EP A3 520949	20-12-98
			FI A0 9323958	28-06-98
			FI A 9323958	28-06-98
			FI A 931513	28-06-98
			FI A0 931513	28-06-98
			FR A1 678169	01-12-98
			FR A1 685706	02-07-98
			FR B1 678169	26-08-98
			FR B1 685706	26-12-98
			GB A0 9311387	14-08-98
			GB A0 9321387	05-08-98
			GB A1 9305735	13-01-98
			GB A0 9305735	01-03-98
			GB A1 9305735	14-06-98
			GB B2 2235795	10-01-98
			GB B2 2235795	14-03-98
			HK A 9371796	12-04-98
			HK A 15776/96	30-08-98
			HU A0 9301975	28-08-98
			HU A2 62201	28-08-98
			IE B 73662	18-06-97
			IL A0 102310	14-01-98
			IL A0 118546	16-10-98
			IL A1 102310	18-03-97
			IL A1 118546	24-09-98
			IT A0 932730476	23-06-98
			JP A2 93186365	27-07-98
			JP A2 93186365	06-06-98
			JP E2 2653958	17-09-97
			KR B1 131064	17-04-98
			LU A 88138	01-03-98
			MX A1 93033336	28-01-98
			NO A0 9322506	25-06-98
			NO A 9322506	28-12-98
			NO A 964382	28-12-98
			NO A0 964382	15-10-98
			NO E1 93033336	05-10-98
			NZ A 242309	24-03-98
			SK A3 1977/92	09-03-98
			SK B6 278759	04-03-98
			ZA A 9204719	27-12-98
			CN A 1079907	29-12-98
			AU E2 688920	19-02-98